Skip to content

Endoscopic and Robotic NSM with Immediate Prosthesis Breast Reconstruction

Prospective Cohort Study of Minimally Invasive Surgery Versus Traditional Open Surgery for Nipple Areola Preserving Mastectomy Combined with Immediate Prosthesis Reconstruction

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06748677
Acronym
EnRoNSM
Enrollment
484
Registered
2024-12-27
Start date
2025-01-03
Completion date
2031-12-31
Last updated
2025-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endoscopic Surgery, Immediate Prosthesis Reconstruction, Nipple-sparing Mastectomy, Robotic Surgery

Brief summary

Breast cancer is the most common malignant tumor in women. Surgical treatment is the most important treatment for early breast cancer. Breast cancer resection is considered to be a destructive operation. Patients need to accept the double blow of physical and psychological loss of breast shape. Although with the change of the concept of early diagnosis and treatment of breast cancer, the breast conserving rate of breast cancer is gradually increasing in China, more than half of the patients are still unable to retain breast due to their condition. For these patients, breast reconstruction surgery is an important means to improve the postoperative breast shape. With the improvement of surgical technology, endoscopic/robotic NSM combined with immediate prosthesis breast reconstruction has been gradually developed. According to previous literature reports, it has good tumor safety and aesthetics, but it is still lack of large-scale prospective results. This project plans to adopt a prospective cohort design, based on the large sample breast disease cohort database established by the breast center of Peking University People's Hospital, and prospectively include patients who receive NSM combined with immediate prosthesis reconstruction under endoscopy/robot and conventional surgery from January 1, 2025 to December 31, 2028. The perioperative complications, tumor safety and patient reported outcomes of the two methods were compared.

Interventions

None listed

Sponsors

Peking University People's Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

1. Underwent surgical treatment at Peking University People's Hospital, with hospitalization records; 2. Preoperative core needle biopsy confirmed breast cancer; 3. The clinical stage of the tumor is stage 0-IIIB; 4)cT≤5cm, cN0/cN1,M0, And there is no tumor invasion of the nipple areola complex, skin, and chest wall; 5\) Intraoperative plan to use non biological patches (such as TiLoop) to partially or completely wrap the prosthesis 6) Signed agreement to participate in this study; 7) Can cooperate to complete the Patient Reported Outcome Measures (PROMs) questionnaire.

Exclusion criteria

1. Lack of clinical pathological data (such as imaging data, pathological data); 2. Pregnancy or lactation period; 3. Patients with metastatic breast cancer or bilateral breast cancer; 4. Have undergone breast conserving surgery/chest radiation therapy before; 5. Patients with nipple areola invasion and subsequent removal of nipple areola complex; 6. Failed to undergo curative surgery;

Design outcomes

Primary

MeasureTime frameDescription
incidence of postoperative complications3 monthsDelayed wound healing, nipple and areola ischemia/necrosis, skin ischemia/necrosis, serum swelling, wound dehiscence/prosthesis exposure, infection, and prosthesis removal occurred within 3 months after surgery.

Secondary

MeasureTime frameDescription
Patient-reported Outcome Measures1 yearBREAST-Q scores, higher scores mean a better outcome
local-regional recurrence5 yearsFrom research enrollment to ipsilateral breast skin, subcutaneous, chest wall, axillary, internal mammary, and supraclavicular lymph node recurrence;
Distant metastasis free survival5 yearsthe time from enrollment in the study to the occurrence of distant recurrence and metastasis;
Disease free survival5 yearsthe time from study enrollment to the first occurrence of the following events defined as failure, including ipsilateral local recurrence, contralateral breast cancer, distant recurrence or death from any cause.

Other

MeasureTime frameDescription
tumour saftey1 weekPathology of residual cavity lavage fluid; Pathology of peripheral edge tissue in breast specimens. If we can see tumour cell in the lavage fluid or breast tissue on the peripheral edge means not safety.

Countries

China

Contacts

Primary Contactyuan peng, doctor
13671287670@163.com86+13671287670

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026